| Program | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Expected Key Milestones |
|---|---|---|---|---|---|---|
| Pacibekitug | ||||||
| Thyroid Eye Disease (TED) | Phase 2b topline data expected in H2 2025 Phase 3 expected to begin in H2 2024 | |||||
| Pacibekitug | ||||||
| Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 2 topline data expected in H1 2025 | |||||
| Pacibekitug | |||
| Thyroid Eye Disease (TED) | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Expected Key Milestone: Phase 2b topline data expected in H2 2025 Phase 3 expected to begin in H2 2024 | |||
| Pacibekitug | |||
| Atherosclerotic Cardiovascular Disease (ASCVD) | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Expected Key Milestone: Phase 2 topline data expected in H1 2025 | |||
We continue to seek additional opportunities for pacibekitug (also known as TOUR006). We continue to identify indications where IL-6 inhibition has shown evidence of clinical benefit despite no formal industry-led development programs as well as indications where we could bring pacibekitug’s differentiated profile forward, capitalizing on external de-risking events.
For more information about our expanded access policy, please view here.
